| Field | Row 1 |
|---|---|
| adsh | 0000920148-25-000059 |
| cik | 920148 |
| name | LABCORP HOLDINGS INC. |
| sic | 8071 |
| countryba | US |
| stprba | NC |
| cityba | BURLINGTON |
| zipba | 27215 |
| bas1 | 358 S MAIN ST |
| bas2 | |
| baph | 3362291127 |
| countryma | US |
| stprma | NC |
| cityma | BURLINGTON |
| zipma | 27215 |
| mas1 | 358 S MAIN ST |
| mas2 | |
| countryinc | |
| stprinc | |
| ein | 992588107 |
| former | LABORATORY CORP OF AMERICA HOLDINGS |
| changed | 19950504 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250429 |
| accepted | 2025-04-29 11:35:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | lh-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000920148-25-000059 | 20250331 | Accounts Receivable Net Current | 2123200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Additional Paid In Capital Common Stock | 2800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Asset Impairment Charges | 2500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 369400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Cost Of Revenue | 2279300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Cost Of Revenue | 2397100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Dividends | 60600000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20241231 | Finance Lease Liability Noncurrent | 74300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Goodwill | 6369700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Income Tax Expense Benefit | 62200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Contract With Customer Asset | -63900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Inventories | -8400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -45000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Intangible Assets Net Excluding Goodwill | 3488900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Issuanceofcommonstockunderemployeeplans | 26700000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Issuanceofcommonstockunderemployeeplans | 26700000.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Net Cash Provided By Used In Financing Activities | -11700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Net Cash Provided By Used In Operating Activities | 18500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Net Income Loss | 228000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Net Restructuring And Other Special Charges | 6400000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Operating Income Loss | -128900000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Corporate; | ||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | -124300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -126100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20241231 | Prepaid Expense Current | 697600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Repayments Of Lines Of Credit | 64800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Repayments Of Senior Debt | 1000000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Revenues | 710900000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biopharma Laboratory Services; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20240331 | Revenues | 2479700000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Diagnostics; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20240331 | Revenues | 2654600000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0000920148-25-000059 | 20250331 | Revenues | 3345100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Share Based Compensation | 32800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Short Term Debt And Along Term Debt Current Maturities | 1000300000.0000 | USD | 0 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Short Term Debt And Along Term Debt Current Maturities | 400000.0000 | USD | 0 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20231231 | Stockholders Equity | 7875000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20231231 | Stockholders Equity | -59300000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20231231 | Stockholders Equity | 7888200000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20241231 | Stockholders Equity | 2800000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20241231 | Accrued Liabilities Current | 871200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -191600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Additional Paid In Capital Common Stock | 35800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 25500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 99300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Common Stock Value | 7600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Depreciation And Amortization Of Leased Assets | 44100000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Depreciation Depletion And Amortization | 154500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Depreciation Depletion And Amortization | 166800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Dividends | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Goodwill | 1289500000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Covance Drug Development; | ||
| 0000920148-25-000059 | 20250331 | Goodwill | 5131600000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Lab Corp Diagnostics; | ||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Accounts Receivable | 170800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -156900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Inventory Net | 493200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Inventory Net | 488300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Issuanceofcommonstockunderemployeeplans | 0.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Issuanceofcommonstockunderemployeeplans | 0.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Issuanceofcommonstockunderemployeeplans | 0.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20241231 | Liabilities | 10312500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Liabilities And Stockholders Equity | 18379000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Net Cash Provided By Used In Operating Activities | -29800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Operating Income Loss | 99900000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biopharma Laboratory Services; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20241231 | Other Assets Noncurrent | 652200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Before Tax | -126700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Tax | 100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Other Liabilities Noncurrent | 517400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Other Liabilities Noncurrent | 497900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Payments Of Dividends | 61600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Payments To Acquire Property Plant And Equipment | 133800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Prepaid Expense Current | 657500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Revenues | 5800000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Intersegment Elimination; | ||
| 0000920148-25-000059 | 20240331 | Share Based Compensation | 31600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Stockholders Equity | 8055300000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Accounts Payable Current | 717900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Income Loss From Equity Method Investments | 100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Accrued Liabilities Current | 770400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -261600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 14700000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 32800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 32800000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20241231 | Deferred Income Taxes And Other Tax Liabilities | 383100000.0000 | USD | 0 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Deferred Income Tax Expense Benefit | -19500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Depreciation And Amortization Of Leased Assets | 48600000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Dividends | 61200000.0000 | USD | 0 | us-gaap/2024 | Dividends= O2025 Q1 Dividends; Subsequent Event Type= Subsequent Event; | ||
| 0000920148-25-000059 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -2900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Gross Profit | 897300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Income Tax Expense Benefit | 69100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Deferred Revenue | -41600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Interest Expense | 56000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Issuanceofcommonstockunderemployeeplans | 0.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20240331 | Net Cash Provided By Used In Investing Activities | -393100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 14700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Amortization Of Intangible Assets | 69600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1518700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Common Stock Value | 7600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Comprehensive Income Net Of Tax | 282800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Deferred Revenue Current | 392200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Operating Lease Liability Current | 184600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | 2400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 259200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Payments To Acquire Equity Method Investments | 151600000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= S Y N L A B; Currency= U S D; | ||
| 0000920148-25-000059 | 20250331 | Payments To Acquire Property Plant And Equipment | 126000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Proceeds From Sale Of Property Plant And Equipment | 500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Stockholders Equity | 7700000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Stockholders Equity | 8307400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Stockholders Equity | -191600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Assets | 17603800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 536800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | 102200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Deferred Income Tax Expense Benefit | -6100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Dividends | 60900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Dividends | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Earnings Per Share Diluted | 2.6900 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Finance Lease Liability Current | 6100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Accounts Receivable | 187100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Inventories | 600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 24900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Liabilities Current | 2064600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Long Term Debt Noncurrent | 600000000.0000 | USD | 0 | us-gaap/2024 | Longterm Debt Type= Senior Notes Due2029 And2034; | ||
| 0000920148-25-000059 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | 69700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | -400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Payments Related To Tax Withholding For Share Based Compensation | 25500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 225000000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Bio Reference Health Oncology Focused; | ||
| 0000920148-25-000059 | 20250331 | Payments To Acquire Equity Method Investments | 157000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Proceeds From Long Term Lines Of Credit | 253200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Proceeds From Payments For Other Financing Activities | -3300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Proceeds From Sale Of Property Plant And Equipment | 100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Property Plant And Equipment Net | 3045400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Retained Earnings Accumulated Deficit | 8455600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20231231 | Stockholders Equity | 7700000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20240331 | Stockholders Equity | -185400000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20240331 | Stockholders Equity | 82000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20241231 | Stockholders Equity | 8052200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Stockholders Equity | 8303400000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Stockholders Equity | 35800000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20241231 | Unbilled Contracts Receivable | 152900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Accounts Receivable Net Current | 1944100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 31600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 31600000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20250331 | Asset Impairment Charges | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Assets Current | 3789700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Cash And Cash Equivalents At Carrying Value | 1518700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -437500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Comprehensive Income Net Of Tax | 101900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | 283000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Deferred Income Taxes And Other Tax Liabilities | 388000000.0000 | USD | 0 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Deferred Revenue Current | 388300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Dividends | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Earnings Per Share Basic | 2.5400 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Earnings Per Share Diluted | 2.5200 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Finance Lease Liability Current | 4800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Goodwill | 1267200000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Covance Drug Development; | ||
| 0000920148-25-000059 | 20240331 | Goodwill And Intangible Asset Impairment | 2500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Accounts Payable | -147600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Intangible Assets Net Excluding Goodwill | 3487200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Liabilities | 9282100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Liabilities And Stockholders Equity | 17603800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Net Income Loss | 228000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Net Income Loss Attributable To Noncontrolling Interest | 200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Noncontrolling Interest Mezzanine Equity | 14300000.0000 | USD | 0 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Operating Lease Liability Current | 182800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Operating Lease Liability Noncurrent | 676300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Operating Lease Liability Noncurrent | 696400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 70000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Other Operating Activities Cash Flow Statement | -3000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 53500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Payments To Acquire Equity Method Investments | 140400000.0000 | EUR | 1 | us-gaap/2024 | Business Acquisition= S Y N L A B; Currency= E U R; | ||
| 0000920148-25-000059 | 20250331 | Proceeds From Long Term Lines Of Credit | 64800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Proceeds From Sales Of Business Affiliate And Productive Assets | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Profit Loss | 228300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Stockholders Equity | 7600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20240331 | Dividends | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Dividends | 60900000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 7900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Goodwill | 6421100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Gross Profit | 948000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 275200000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Income Loss From Equity Method Investments | -300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Investment Income Net | 2900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Investments In Affiliates Subsidiaries Associates And Joint Ventures | 16300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Liabilities Current | 3330200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Long Term Debt Noncurrent | 5568700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Net Cash Provided By Used In Financing Activities | -839700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20240331 | Net Proceeds From Issuance Of Stock To Employees | 26700000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Noncontrolling Interest Mezzanine Equity | 14300000.0000 | USD | 0 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Operating Income Loss | 321300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Operating Income Loss | 106900000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biopharma Laboratory Services; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20250331 | Operating Income Loss | 534400000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20250331 | Other Assets Noncurrent | 647000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Before Tax | 70100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -126100000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 70000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20240331 | Other Comprehensive Income Loss Tax | -600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Other Nonoperating Income Expense | 20000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Other Nonoperating Income Expense | -1000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Payments Of Dividends | 62100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Proceeds From Accounts Receivable Securitization | 225000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Property Plant And Equipment Net | 3090800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Retained Earnings Accumulated Deficit | 8303400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Revenues | 14000000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Intersegment Elimination; | ||
| 0000920148-25-000059 | 20250331 | Stockholders Equity | 8455600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20240331 | Amortization Of Intangible Assets | 60100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Assets Current | 4806500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Dividends | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20240331 | Earnings Per Share Basic | 2.7100 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Goodwill | 5102500000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Lab Corp Diagnostics; | ||
| 0000920148-25-000059 | 20240331 | Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 297400000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Increase Decrease In Accounts Payable | -121100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -174700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Investment Income Net | 6500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Investments In Affiliates Subsidiaries Associates And Joint Ventures | 168000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Issuanceofcommonstockunderemployeeplans | 0.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20250331 | Issuanceofcommonstockunderemployeeplans | 25700000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Issuanceofcommonstockunderemployeeplans | 25700000.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20250331 | Net Cash Provided By Used In Investing Activities | -336000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Net Income Loss | 212800000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000920148-25-000059 | 20240331 | Net Income Loss Attributable To Noncontrolling Interest | 300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Operating Income Loss | 417900000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Diagnostics; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20240331 | Operating Income Loss | 517800000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20250331 | Operating Income Loss | 427500000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Diagnostics; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20240331 | Payments Related To Tax Withholding For Share Based Compensation | 14700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Proceeds From Accounts Receivable Securitization | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Proceeds From Payments For Other Financing Activities | -4000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Profit Loss | 213000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Revenues | 3176600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Revenues | 2629600000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Diagnostics; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20250331 | Selling General And Administrative Expense | 546000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Accounts Payable Current | 875800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 25500000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20241231 | Assets | 18379000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Cash And Cash Equivalents At Carrying Value | 369400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -1149300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Common Stock Shares Outstanding | 83400000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Common Stock Shares Outstanding | 83800000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Dividends | 60600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Dividends | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20250331 | Finance Lease Liability Noncurrent | 66500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Goodwill And Intangible Asset Impairment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Contract With Customer Asset | -3900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Increase Decrease In Deferred Revenue | -8900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Interest Expense | 46900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Issuanceofcommonstockunderemployeeplans | 0.0000 | USD | 1 | 0000920148-25-000059 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20241231 | Long Term Debt Noncurrent | 5331200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Net Income Loss | 212800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Net Proceeds From Issuance Of Stock To Employees | 25700000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20240331 | Net Restructuring And Other Special Charges | 5000000.0000 | USD | 1 | 0000920148-25-000059 | |||
| 0000920148-25-000059 | 20250331 | Operating Income Loss | 326000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Operating Income Loss | -132400000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Corporate; | ||
| 0000920148-25-000059 | 20250331 | Other Operating Activities Cash Flow Statement | 8100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Payments To Acquire Equity Method Investments | 13700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Proceeds From Sales Of Business Affiliate And Productive Assets | 13500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Repayments Of Lines Of Credit | 210800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20240331 | Repayments Of Senior Debt | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20250331 | Revenues | 721300000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biopharma Laboratory Services; Consolidation Items= Operating Segments; | ||
| 0000920148-25-000059 | 20250331 | Revenues | 2813800000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0000920148-25-000059 | 20240331 | Selling General And Administrative Expense | 508400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20231231 | Stockholders Equity | 38400000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000920148-25-000059 | 20240331 | Stockholders Equity | 7959600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000920148-25-000059 | 20241231 | Stockholders Equity | -261600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000920148-25-000059 | 20241231 | Stockholders Equity | 7600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000920148-25-000059 | 20250331 | Unbilled Contracts Receivable | 151300000.0000 | USD | 0 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Payments To Acquire Equity Method Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Equity Method Investments | The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Finance Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Finance Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Income (Loss) Attributable to Noncontrolling Interest | Amount of Net Income (Loss) attributable to noncontrolling interest. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax | Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Payments Of Dividends | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Dividends | Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Deferred Revenue Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Revenue, Current | Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. |
| Short Term Debt And Along Term Debt Current Maturities | 0000920148-25-000059 | 1 | 0 | monetary | I | C | Short Term Debt and Along Term Debt Current Maturities | Short Term Debt and Along Term Debt Current Maturities |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Adjustments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation | Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. |
| Asset Impairment Charges | us-gaap/2024 | 0 | 0 | monetary | D | D | Asset Impairment Charges | Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. |
| Dividends | us-gaap/2024 | 0 | 0 | monetary | D | D | Dividends | Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Goodwill And Intangible Asset Impairment | us-gaap/2024 | 0 | 0 | monetary | D | D | Goodwill and Intangible Asset Impairment | Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | us-gaap/2024 | 0 | 0 | monetary | I | D | Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures | Amount of investment in equity method investee and investment in and advance to affiliate. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Other Operating Activities Cash Flow Statement | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Operating Activities, Cash Flow Statement | Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). |
| Prepaid Expense Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Unbilled Contracts Receivable | us-gaap/2024 | 0 | 0 | monetary | I | D | Unbilled Contracts Receivable | Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Depreciation And Amortization Of Leased Assets | 0000920148-25-000059 | 1 | 0 | monetary | D | D | Depreciation And Amortization Of Leased Assets | The amount of depreciation recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Also, may include amortization charged against earnings for the periodic recognition of capitalized leases. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Gross Profit | us-gaap/2024 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Interest Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Net Proceeds From Issuance Of Stock To Employees | 0000920148-25-000059 | 1 | 0 | monetary | D | D | Net proceeds from issuance of stock to employees | The cash inflow associated with the amount received from holders exercising their stock options and employees related to shares purchased under the employee stock purchase plan. |
| Proceeds From Sales Of Business Affiliate And Productive Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sales of Business, Affiliate and Productive Assets | Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities. |
| Repayments Of Senior Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Senior Debt | The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Cost Of Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Revenue | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Deferred Income Taxes And Other Tax Liabilities | 0000920148-25-000059 | 1 | 0 | monetary | I | C | Deferred income taxes and other tax liabilities | Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax, combined with the noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax | Amount after tax and reclassification adjustments of other comprehensive income (loss). |
| Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Property, Plant, and Equipment | The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Deferred Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | Amount of increase (decrease) in accrued expenses, and obligations classified as other. |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Proceeds From Long Term Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Long-Term Lines of Credit | The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Proceeds From Payments For Other Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from (Payments for) Other Financing Activities | Amount of cash inflow (outflow) from financing activities classified as other. |
| Issuanceofcommonstockunderemployeeplans | 0000920148-25-000059 | 1 | 0 | monetary | D | D | Issuance of common stock under employee plans | Aggregate change in value for stock issued in period under ESPP combined with the value of stock issued as a result of option exercises. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Income Loss From Equity Method Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Equity Method Investments | Amount of income (loss) for proportionate share of equity method investee's income (loss). |
| Increase Decrease In Contract With Customer Asset | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Contract with Customer, Asset | Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Investment Income Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Net | Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment, Tax Withholding, Share-Based Payment Arrangement | Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. |
| Net Restructuring And Other Special Charges | 0000920148-25-000059 | 1 | 0 | monetary | D | D | Net restructuring and other special charges | Amount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program planned and controlled by management, and materially changes either the scope or manner of conduct of a business undertaken. Also, may include reversals and other adjustments to accrued liabilities and special charges, if any, for asset abandonment, uncollectible balances, etc. |
| Noncontrolling Interest Mezzanine Equity | 0000920148-25-000059 | 1 | 0 | monetary | I | C | Noncontrolling Interest Mezzanine Equity | Represents contractual value of a noncontrolling interest put (includes underlying noncontrolling interest). In February 2010, the Company completed a transaction to sell the partnership units acquired from the previous noncontrolling interest holder to a new Canadian partner. As a result of this transaction, the Company recorded a component of noncontrolling interest in liabilities and a component in mezzanine equity. This item represents the mezzanine equity component. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax | Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan. |
| Other Comprehensive Income Loss Tax | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Comprehensive Income (Loss), Tax | Amount of tax expense (benefit) allocated to other comprehensive income (loss). |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Proceeds From Accounts Receivable Securitization | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Accounts Receivable Securitization | Proceeds from securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions. |
| Repayments Of Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Lines of Credit | Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. |
| Finance Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Finance Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from finance lease, classified as current. |
| Increase Decrease In Deferred Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Other Comprehensive Income Loss Before Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), before Tax | Amount before tax, after reclassification adjustments of other comprehensive income (loss). |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 0000920148-25-000059 | 1 | 0 | monetary | D | C | Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest | Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000920148-25-000059 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000920148-25-000059 | 2 | 4 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0000920148-25-000059 | 2 | 5 | BS | 0 | H | Unbilled Contracts Receivable | us-gaap/2024 | Unbilled services | 0 |
| 0000920148-25-000059 | 2 | 6 | BS | 0 | H | Inventory Net | us-gaap/2024 | Supplies inventory | 0 |
| 0000920148-25-000059 | 2 | 7 | BS | 0 | H | Prepaid Expense Current | us-gaap/2024 | Prepaid expenses and other | 0 |
| 0000920148-25-000059 | 2 | 8 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000920148-25-000059 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property, plant, and equipment, net | 0 |
| 0000920148-25-000059 | 2 | 10 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill, net | 0 |
| 0000920148-25-000059 | 2 | 11 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0000920148-25-000059 | 2 | 12 | BS | 0 | H | Investments In Affiliates Subsidiaries Associates And Joint Ventures | us-gaap/2024 | Joint venture partnerships and equity method investments | 0 |
| 0000920148-25-000059 | 2 | 13 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets, net | 0 |
| 0000920148-25-000059 | 2 | 14 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000920148-25-000059 | 2 | 17 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000920148-25-000059 | 2 | 18 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses and other | 0 |
| 0000920148-25-000059 | 2 | 19 | BS | 0 | H | Deferred Revenue Current | us-gaap/2024 | Unearned revenue | 0 |
| 0000920148-25-000059 | 2 | 20 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Short-term operating lease liabilities | 0 |
| 0000920148-25-000059 | 2 | 21 | BS | 0 | H | Finance Lease Liability Current | us-gaap/2024 | Short-term finance lease liabilities | 0 |
| 0000920148-25-000059 | 2 | 22 | BS | 0 | H | Short Term Debt And Along Term Debt Current Maturities | 0000920148-25-000059 | Short-term borrowings and current portion of long-term debt | 0 |
| 0000920148-25-000059 | 2 | 23 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000920148-25-000059 | 2 | 24 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt | 0 |
| 0000920148-25-000059 | 2 | 25 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating lease liabilities | 0 |
| 0000920148-25-000059 | 2 | 26 | BS | 0 | H | Finance Lease Liability Noncurrent | us-gaap/2024 | Financing lease liabilities | 0 |
| 0000920148-25-000059 | 2 | 27 | BS | 0 | H | Deferred Income Taxes And Other Tax Liabilities | 0000920148-25-000059 | Deferred income taxes and other tax liabilities | 0 |
| 0000920148-25-000059 | 2 | 28 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other liabilities | 0 |
| 0000920148-25-000059 | 2 | 29 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000920148-25-000059 | 2 | 31 | BS | 0 | H | Noncontrolling Interest Mezzanine Equity | 0000920148-25-000059 | Noncontrolling interest | 0 |
| 0000920148-25-000059 | 2 | 32 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000920148-25-000059 | 2 | 33 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock 83.8 and 83.4 shares outstanding at March 31, 2025, and December 31, 2024, respectively | 0 |
| 0000920148-25-000059 | 2 | 34 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Retained earnings | 1 |
| 0000920148-25-000059 | 2 | 35 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0000920148-25-000059 | 2 | 36 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total shareholders equity | 0 |
| 0000920148-25-000059 | 2 | 37 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and shareholders equity | 0 |
| 0000920148-25-000059 | 3 | 9 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock 83.8 and 83.4 shares outstanding at March 31, 2025, and December 31, 2024, respectively | 0 |
| 0000920148-25-000059 | 4 | 1 | IS | 0 | H | Revenues | us-gaap/2024 | Revenues | 0 |
| 0000920148-25-000059 | 4 | 2 | IS | 0 | H | Cost Of Revenue | us-gaap/2024 | Cost of Revenue | 0 |
| 0000920148-25-000059 | 4 | 3 | IS | 0 | H | Gross Profit | us-gaap/2024 | Gross profit | 0 |
| 0000920148-25-000059 | 4 | 4 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general, and administrative expenses | 0 |
| 0000920148-25-000059 | 4 | 5 | IS | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of intangibles and other assets | 0 |
| 0000920148-25-000059 | 4 | 6 | IS | 0 | H | Asset Impairment Charges | us-gaap/2024 | Goodwill and other asset impairments | 0 |
| 0000920148-25-000059 | 4 | 7 | IS | 0 | H | Net Restructuring And Other Special Charges | 0000920148-25-000059 | Restructuring and other charges | 0 |
| 0000920148-25-000059 | 4 | 8 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Operating income | 0 |
| 0000920148-25-000059 | 4 | 9 | IS | 0 | H | Interest Expense | us-gaap/2024 | Interest expense | 1 |
| 0000920148-25-000059 | 4 | 10 | IS | 0 | H | Investment Income Net | us-gaap/2024 | Investment income | 0 |
| 0000920148-25-000059 | 4 | 11 | IS | 0 | H | Income Loss From Equity Method Investments | us-gaap/2024 | Equity method (loss) income, net | 0 |
| 0000920148-25-000059 | 4 | 12 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other, net | 0 |
| 0000920148-25-000059 | 4 | 13 | IS | 0 | H | Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 0000920148-25-000059 | Earnings from operations before income taxes | 0 |
| 0000920148-25-000059 | 4 | 14 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Provision for income taxes | 0 |
| 0000920148-25-000059 | 4 | 15 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net earnings | 0 |
| 0000920148-25-000059 | 4 | 16 | IS | 0 | H | Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | Less: Net earnings attributable to the noncontrolling interest | 1 |
| 0000920148-25-000059 | 4 | 17 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net earnings attributable to Labcorp Holdings Inc. | 0 |
| 0000920148-25-000059 | 4 | 18 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic earnings per share | 0 |
| 0000920148-25-000059 | 4 | 19 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted earnings per share | 0 |
| 0000920148-25-000059 | 5 | 3 | CI | 0 | H | Profit Loss | us-gaap/2024 | Net earnings | 0 |
| 0000920148-25-000059 | 5 | 4 | CI | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | us-gaap/2024 | Foreign currency translation adjustments | 0 |
| 0000920148-25-000059 | 5 | 5 | CI | 0 | H | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | us-gaap/2024 | Net benefit plan adjustments | 1 |
| 0000920148-25-000059 | 5 | 6 | CI | 0 | H | Other Comprehensive Income Loss Before Tax | us-gaap/2024 | Other comprehensive earnings (loss) before tax | 0 |
| 0000920148-25-000059 | 5 | 7 | CI | 0 | H | Other Comprehensive Income Loss Tax | us-gaap/2024 | Provision for income tax related to items of comprehensive earnings | 1 |
| 0000920148-25-000059 | 5 | 8 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Other comprehensive earnings (loss), net of tax | 0 |
| 0000920148-25-000059 | 5 | 9 | CI | 0 | H | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Comprehensive earnings | 0 |
| 0000920148-25-000059 | 5 | 10 | CI | 0 | H | Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | Less: Net earnings attributable to the noncontrolling interest | 1 |
| 0000920148-25-000059 | 5 | 11 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive earnings attributable to Labcorp Holdings Inc. | 0 |
| 0000920148-25-000059 | 6 | 9 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | BALANCE | 0 |
| 0000920148-25-000059 | 6 | 10 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net earnings attributable to Labcorp Holdings Inc. | 0 |
| 0000920148-25-000059 | 6 | 11 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Other comprehensive earnings, net of tax | 0 |
| 0000920148-25-000059 | 6 | 12 | EQ | 0 | H | Dividends | us-gaap/2024 | Dividends | 0 |
| 0000920148-25-000059 | 6 | 13 | EQ | 0 | H | Issuanceofcommonstockunderemployeeplans | 0000920148-25-000059 | Issuance of common stock under employee stock plans | 1 |
| 0000920148-25-000059 | 6 | 14 | EQ | 0 | H | Adjustments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Surrender of restricted stock and performance share awards | 1 |
| 0000920148-25-000059 | 6 | 15 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock compensation | 0 |
| 0000920148-25-000059 | 6 | 16 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | BALANCE | 0 |
| 0000920148-25-000059 | 6 | 17 | EQ | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Retained Earnings (Accumulated Deficit) | 0 |
| 0000920148-25-000059 | 7 | 4 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net earnings | 0 |
| 0000920148-25-000059 | 7 | 6 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0000920148-25-000059 | 7 | 7 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock compensation | 0 |
| 0000920148-25-000059 | 7 | 8 | CF | 0 | H | Depreciation And Amortization Of Leased Assets | 0000920148-25-000059 | Operating lease right-of-use asset expense | 0 |
| 0000920148-25-000059 | 7 | 9 | CF | 0 | H | Goodwill And Intangible Asset Impairment | us-gaap/2024 | Goodwill and other asset impairments | 0 |
| 0000920148-25-000059 | 7 | 10 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2024 | Deferred income taxes | 0 |
| 0000920148-25-000059 | 7 | 11 | CF | 0 | H | Other Operating Activities Cash Flow Statement | us-gaap/2024 | Other, net | 0 |
| 0000920148-25-000059 | 7 | 13 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Increase in accounts receivable | 1 |
| 0000920148-25-000059 | 7 | 14 | CF | 0 | H | Increase Decrease In Contract With Customer Asset | us-gaap/2024 | Decrease in unbilled services | 1 |
| 0000920148-25-000059 | 7 | 15 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Decrease (increase) in supplies inventory | 1 |
| 0000920148-25-000059 | 7 | 16 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Decrease (increase) in prepaid expenses and other | 0 |
| 0000920148-25-000059 | 7 | 17 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Decrease in accounts payable | 0 |
| 0000920148-25-000059 | 7 | 18 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2024 | Decrease in unearned revenue | 0 |
| 0000920148-25-000059 | 7 | 19 | CF | 0 | H | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | us-gaap/2024 | Decrease in accrued expenses and other | 0 |
| 0000920148-25-000059 | 7 | 20 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net Cash Provided by (Used in) Operating Activities, Total | 0 |
| 0000920148-25-000059 | 7 | 22 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Capital expenditures | 1 |
| 0000920148-25-000059 | 7 | 23 | CF | 0 | H | Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | Proceeds from sale of assets | 0 |
| 0000920148-25-000059 | 7 | 24 | CF | 0 | H | Proceeds From Sales Of Business Affiliate And Productive Assets | us-gaap/2024 | Proceeds from sale of business | 0 |
| 0000920148-25-000059 | 7 | 25 | CF | 0 | H | Payments To Acquire Equity Method Investments | us-gaap/2024 | Investments in equity affiliates | 1 |
| 0000920148-25-000059 | 7 | 26 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | Acquisition of businesses, net of cash acquired | 1 |
| 0000920148-25-000059 | 7 | 27 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used for investing activities | 0 |
| 0000920148-25-000059 | 7 | 29 | CF | 0 | H | Repayments Of Senior Debt | us-gaap/2024 | Payments on senior notes | 1 |
| 0000920148-25-000059 | 7 | 30 | CF | 0 | H | Proceeds From Long Term Lines Of Credit | us-gaap/2024 | Proceeds from revolving credit facilities | 0 |
| 0000920148-25-000059 | 7 | 31 | CF | 0 | H | Repayments Of Lines Of Credit | us-gaap/2024 | Payments on revolving credit facilities | 1 |
| 0000920148-25-000059 | 7 | 32 | CF | 0 | H | Proceeds From Accounts Receivable Securitization | us-gaap/2024 | Proceeds from accounts receivable securitization | 0 |
| 0000920148-25-000059 | 7 | 33 | CF | 0 | H | Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Net share settlement tax payments from issuance of stock to employees | 0 |
| 0000920148-25-000059 | 7 | 34 | CF | 0 | H | Net Proceeds From Issuance Of Stock To Employees | 0000920148-25-000059 | Net proceeds from issuance of stock to employees | 0 |
| 0000920148-25-000059 | 7 | 35 | CF | 0 | H | Payments Of Dividends | us-gaap/2024 | Dividends paid | 0 |
| 0000920148-25-000059 | 7 | 36 | CF | 0 | H | Proceeds From Payments For Other Financing Activities | us-gaap/2024 | Other | 0 |
| 0000920148-25-000059 | 7 | 37 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash used for financing activities | 0 |
| 0000920148-25-000059 | 7 | 38 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Effect of exchange rate changes on Cash and cash equivalents | 0 |
| 0000920148-25-000059 | 7 | 39 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash and cash equivalents | 0 |
| 0000920148-25-000059 | 7 | 40 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents at beginning of period | 0 |
| 0000920148-25-000059 | 7 | 41 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents at end of period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |